Nkiruka Ezenwajiaku

Nkiruka Ezenwajiaku

Oncology

8100 Southwest 10th Street
Plantation, FL 33324

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.

Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.

Journal: Gastroenterology & hepatology

Published: May 26, 2025

Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.

Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.

Journal: JCO precision oncology

Published: May 22, 2025

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.

Journal: JCO precision oncology

Published: December 03, 2024

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma.

Journal: Haematologica

Published: May 02, 2023

Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race.

Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race.

Journal: Cancer medicine

Published: September 07, 2022

Showing 1-5 of 5

Last Updated: 09/26/2026